New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
08:14 EDTEPZMEpizyme announces publication of preclinical data for EPZ-6438
Epizyme announced the publication of data from preclinical studies of the company's clinical candidate EPZ-6438, a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase. Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma, implicating EZH2 as a therapeutic target in these patients. Detailed characterization of the correlation between EZH2 inhibition, methylation of the EZH2 target (H3K27), reversal of lymphomagenic gene expression and antiproliferative effects specific to EZH2 mutant-bearing NHL cell lines. Sustained tumor growth inhibition in animal models of EZH2 mutant-bearing NHL, including durable effects after drug dosing is discontinued.
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:05 EDTEPZMEpizyme names Peter Ho as Chief Development Officer
Epizyme announced the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development. Ho will lead Epizyme’s clinical development, regulatory and translational medicine functions. Shih will lead Epizyme’s partnership strategy and execution.
September 12, 2014
10:00 EDTEPZMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:27 EDTEPZMEpizyme initiated with a Buy at Mizuho
Target $35.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use